Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | BRS3 | P32247 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26748609 | 0.81 | PLK1 (0.39) | LMNATAAR1 | |
| SCHEMBL6685103 | 0.76 | ESR1 (0.74) | ESR1ESR2THRATHRBSLC6A2 | |
| SCHEMBL19454941 | 0.75 | ESR1 (0.58) | ESR1ESR2THRATHRBLMNA | |
| SCHEMBL18591715 | 0.73 | TSHR (0.52) | — | |
| SCHEMBL19464746 | 0.72 | ESR1 (0.41) | ESR1ESR2THRATHRB | |
| SCHEMBL1691810 | 0.71 | ESR1 (0.54) | ESR1ESR2THRATHRBTAAR1 | |
| SCHEMBL19772887 | 0.71 | ESR1 (0.54) | ESR1ESR2THRATHRBSLC6A2 | |
| SCHEMBL13555478 | 0.71 | ESR1 (0.54) | ESR1ESR2THRATHRBSLC6A2 | |
| SCHEMBL8254374 | 0.70 | KCNN4 (0.44) | ESR1ESR2TAAR1 | |
| SCHEMBL11955108 | 0.70 | ESR1 (0.58) | ESR1ESR2THRATHRBSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | ESR1 1132/4885ESR2 2108/4885THRA 2185/4885 |
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | ESR1 1237/4885ESR2 1396/4885THRA 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.